. We reviewed the current literature to evaluate the efficacy of antimicrobialimpregnated CVCs for preventing CRBSI. Eleven randomized studies published in article form were identified that included a control group that received nonimpregnated CVCs. We evaluated study methodologies, inclusion of key patient characteristics, use of clinically relevant end points, and molecular-relatedness studies. Review of these 11 trials revealed several methodological flaws, including inconsistent definitions of CRBSI, failure to account for confounding variables, suboptimal statistical and epidemiological methods, and rare use of clinically relevant end points. This review also failed to demonstrate any significant clinical benefit associated with the use of antimicrobial-impregnated CVCs for the purpose of reducing CRBSI or improving patient outcomes. More rigorous studies are required to support or refute the hypothesis that antimicrobialimpregnated CVCs reduce the rate of or prevent CRBSI.
In the United States, nosocomial bloodstream infections (BSIs) are reported to occur at a rate of 1200,000 cases per year and to account for 3.5 million additional hospital days and $3.5 billion in costs [1] . Twenty percent of BSIs are thought to be associated with the use of central venous catheters (CVCs) [2] . On the assumption that the skin is the primary source of catheter-related bloodstream infections (CRBSIs), efforts have focused on preventing these infections by impregnating CVCs with combinations of antimicrobial agents [1] . There are 2 commercially available antimicrobial-impregnated CVCs. One uses a combination of chlorhexidine and silver sulfadiazine, and the other uses a combination of minocycline and rifampin. The Hospital Infection Control Practice Advisory Committee and other investigators have published guidelines that recommend the use of these impregnated CVCs to prevent CRBSI [3] [4] [5] [6] . Two recent analyses also concluded that catheters impregnated with the antimicrobial combination of chlorhexidine and silver sulfadiazine were efficacious [7] and costeffective [8] . However, the use of antimicrobial-impregnated CVCs remains controversial because of concerns about the emergence of antimicrobial resistance, the cost, and questionable efficacy rates. The primary objective of our review was to evaluate the evidence supporting the claim that antimicrobial-impregnated CVCs are effective at preventing CRBSI and improving patient outcome. In addition, we reviewed the cost-effectiveness of these catheters, focusing on the evidence found in our primary review.
METHODS

Data sources.
A MEDLINE literature search of articles published from 1966 through May 2001 was performed with the following medical search heading (MeSH) index terms: "bacteremia" or "septicemia"; "antibiotics," "anti-infective agents," or "anti-infective agents, local"; "catheterization, central venous" or "venous catheter"; and "antiseptic," "sulfadiazine," "chlorhexidine," "germicidal," "germicide," "minocycline," or "rifampin." This search identified 58 references.
Study selection.
Studies were included if they were randomized, included a control group who used CVCs that were not impregnated with an antimicrobial, and published in article form. Of the 58 references identified, 11 met these criteria [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] .
Data extraction. We extracted the following information from these studies: (1) number of patients and number of CVCs placed, (2) types of control and experimental CVCs placed, (3) clinical setting, (4) number of experimental and control CVCs associated with BSI, (5) efficacy rate of experimental and control CVCs in the prevention of CRBSI, (6) organisms responsible for CRBSI in both experimental and control groups, (7) catheter-related adverse events, and (8) duration of catheterization with control and experimental CVCs. We also evaluated study methodologies (definitions, epidemiological tools, and statistical analysis), inclusion of key patient characteristics (severity of illness and degree of immunosuppression), use of clinically relevant end points (length of hospital stay, survival, therapeutic antibiotic use, and duration of CVC retention), and use of molecular-relatedness tests linking onset of CRBSIs to use of CVCs.
Data synthesis. Patient populations evaluated in these 11 studies included patients in an intensive care unit (ICU), recipients of transplants (solid organ or bone marrow), patients with cancer, patients who had recently undergone surgery, and patients who were receiving total parenteral nutrition [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] . Patient characteristics and the significant statistical comparisons between study and control groups with regard to type of impregnated CVC inserted, type of patient population, incidence of catheter-based bacterial colonization, rate of CRBSI, duration of CVC retention, duration of hospital stay, mortality, and incidence of adverse events are presented in table 1 [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] . Additional data, including the presence and content of the definition of CRBSI; the presence of confounding variables; the statistical and epidemiological methods, culture methods, and molecular relatedness studies used; and the effect of antimicrobial impregnation of CVCs on clinical end points are summarized in table 2 [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] .
RESULTS
A lower rate of bacterial colonization of antimicrobial-impregnated CVCs was reported in 8 studies [10-12, 14-16, 18, 19] , and a reduction in the rate of CRBSI was reported in 2 studies [10, 18] . In 0 of the 11 studies was antimicrobial impregnation of CVCs associated with an improvement in the duration of CVC retention or with a reduction in therapeutic antibiotic use, duration of ICU or hospital stay, or overall mortality [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] . Our review of the evidence reported in these 11 studies also revealed several methodological flaws.
Inconsistent and/or incomplete definitions. All 11 studies used different definitions of CRBSI [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] . Definitions ranged from isolation of the same species from a CVC tip and from culture of either urine, a single peripheral-blood sample, or another CVC, to the requirement that organisms isolated from a CVC tip and from a peripheral-blood culture have the same antimicrobial susceptibility profile or genotype (table 2) [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] . An important aspect of the definition of CRBSI is the number of blood cultures positive for skin contaminants [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] . Ten (91%) of the studies either failed to disclose their definition of BSI [16] or failed to include the number of blood cultures positive for coagulase-negative staphylococcus (CONS). This organism accounted for the majority of CRBSIs in these studies and is a common skin contaminant [9] [10] [11] [12] [13] [14] [15] [17] [18] [19] .
Missing key confounding variables. Known prognostic factors for CRBSI were not included in most of these studies [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] . For example, severity-of-illness score and degree of immunosuppression were not reported in 9 [9, [11] [12] [13] [14] [15] [16] [17] [18] and 8 of these studies [9, 11-15, 17, 19] , respectively, and the organism responsible for CRBSI was not described in 2 studies [16, 19] . None of the 11 studies evaluated the number of CRBSI episodes per day at risk, a key end point in studies of CRBSI [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] . In addition, some studies allowed for the inclusion of other confounding variables, such as presence of an arterial CVC (4 studies) [10] [11] [12] 19] or allowance for guidewire exchange (4 studies) [10, 11, 13, 15] .
Inadequate statistical or epidemiological methods. None of the studies included an intent-to-treat analysis [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] , and 9 did not report on investigator blinding [9, [11] [12] [13] [14] [15] [16] [17] 19] . Sample size and power calculations were not provided in 10 studies [9, 10, [12] [13] [14] [15] [16] [17] [18] [19] , and the only study that provided this information was powered to detect a reduction in the rate of CVC bacterial colonization but not in the rate of CRBSI [11] . Seven studies did not report 95% CIs [9, 11-13, 15, 16, 19] , and data for the number of infections per 1000 CVC days, a benchmark for evaluating CRBSI, was also not used in 7 studies [11-14, 16, 17, 19] .
Lack of molecular relatedness testing. The molecular relatedness of organisms recovered from CVC tips and from blood samples was evaluated in only 3 studies [10, 12, 18] .
Limited reporting of clinically relevant end points. None of the 11 studies reported the duration of ICU stay [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] , and only 5 collected data on use of therapeutic antibiotics [11, 12, [16] [17] [18] or the occurrence of adverse events associated with CVC use [10, 12, 15, 16, 18] . Eight studies did not report the duration of hospitalization [10-12, 14, 16-19] or overall mortality [9-12, 14, 16-18] , and 2 failed to report the duration of CVC retention [12, 16] .
DISCUSSION
Our analysis revealed that the data supporting the benefits of using antimicrobial-impregnated CVCs for preventing CRBSIs suffer from the significant methodological flaws of the source studies. These flaws include the use of improper 
Statistical and epidemiological methods
Evaluation of clinically relevant end points
Overall rate of infection - definitions and suboptimal epidemiological and statistical tools, omission of key prognostic variables, lack of consistent attempts to determine the relatedness of bloodstream and CVC isolates or to examine clinically relevant end points, and the inclusion of important confounding variables. We could not identify consistent benefits associated with the use of antimicrobial-impregnated CVCs in any of the clinically relevant end points reported by the investigators, such as reductions in the rate of CRBSI, the duration of CVC retention, therapeutic antibiotic use, duration of hospital or ICU stay, or survival. A reduction in the rate of bacterial colonization of antimicrobial-impregnated CVCs was observed in 8 studies [10, 11, 14-16, 18, 19] . However, in only 2 studies did this reduction translate into a lower rate of CRBSI [10, 18] . Furthermore, bacterial colonization of CVCs does not necessarily imply a high rate of CRBSI. This is exemplified by one of these studies, in which most CVCs were removed because they were no longer medically necessary [19] . In this subset of patients, ∼30% of both control and antimicrobial-impregnated CVCs were colonized at the time of removal [19] . Yet none of these patients had CRBSI or any other sign of infection [19] .
Two studies reported a reduction in the rate of CRBSI that was associated with the use of antimicrobial-impregnated CVCs [10, 18] . Unfortunately, both studies suf-fered from some of the methodological flaws mentioned above (table 2) , and, in one study, the decrease in the rate of CRBSI was almost exclusively due to a reduction in the rate of CRBSI due to CONS (6 of 7 infections) [18] . In this latter study, a single blood culture positive for CONS was acceptable for the diagnosis of CRBSI. However, the estimated positive predictive value of a single blood culture positive for CONS for the diagnosis of true BSI is only 2% [27] . In addition, the majority (70%-92%) of blood isolates of CONS are not thought to represent active infection [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] , especially when a single blood sample yields this organism on culture [27] . Therefore, the significance of the rate of CRBSI reduction due to the use of antimicrobial impregnated CVCs in this study [18] should be reevaluated.
The rationale for using antimicrobialimpregnated CVCs is that CRBSIs originate from a patient's skin at the site of CVC insertion. Therefore, the impregnation of CVCs with antimicrobial agents may prevent colonization of CVCs by skin organisms and, subsequently, CRBSI. There is, however, controversy regarding the site of origin of CRBSIs [34] [35] [36] . Furthermore, recovery of the same species from specimens of blood and skin (or the CVC tip) does not necessarily imply similarity, because CONS, the most common CRBSI isolates, exhibit significant genetic heterogeneity [37] [38] [39] [40] [41] . In addition, the exact origin of CONS that are associated with CRBSI has been disputed in studies employing molecular relatedness testing techniques [42] [43] [44] [45] [46] [47] [48] [49] . These studies suggest that bacteria causing CRBSIs may also originate from mucosal colonization. This may, in part, explain the lack of a consistent reduction in the rate of CRBSI associated with the use of antimicrobialimpregnated CVCs.
CRBSIs reportedly are associated with high attributable mortality [2, 3, 50, 51] . This concern has frequently been used to advocate the use of antimicrobial-impregnated CVCs. However, only 2 studies have documented high attributable mortality, and neither controlled for severity of illness [2, 50] . Yet severity of illness is the single most important prognostic factor for BSI [52] [53] [54] [55] [56] [57] [58] . The importance of considering severity of illness when an assessment of attributable mortality related to CRBSI is made was recently demonstrated in a matched cohort of patients with CVCs in the ICU who were or were not exposed to CRBSIs [53] . In that study, univariate analysis demonstrated greater mortality in the exposed group than in the unexposed group ( ) [53] . How-P p .03 ever, the significant difference was not observed when multivariate analysis that included severity of illness was performed ( ) [53] . The authors of this report P p .27 concluded that "the increased mortality observed in patients who develop CRBSI is explained mostly by increasing severity of their illness before infection" [53, p. 401 ]. An accompanying editorial stated that the high attributable mortality found in prior studies may have resulted from deficiencies in study design and lack of adequate adjustment for confounding variables such as performance status and underlying diseases. "Consequently, the possibility of reducing the risk of death by preventing CRBSI in the ICU seems unrealistic" [54, p. 393] .
When severity of illness was controlled for in 3 larger and more recent studies, attributable mortality due to CRBSI could not be identified [53, 57, 58] . A recent meta-analysis of 449 studies concluded that the attributable mortality of CRBSI was only 2% and that the high mortality observed among patients with CRBSI was due to their underlying diseases [59] . This is further supported by a recent review in which the author argued that the attributable mortality due to CRBSI would have to be 3-fold higher than that due to AIDS and 11-fold higher than that due to primary nosocomial BSI, if the reported high rates of attributable CRBSI mortality were correct [60] .
The premise that there are significant costs associated with CRBSI has also been utilized to justify the use of antimicrobial-impregnated CVCs [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] . However, there are few data to support this assertion.
A cost analysis of the same chlorhexidine-and silver sulfadiazine-impregnated CVC studies we reviewed [9] [10] [11] [12] [13] [14] [15] [16] [17] 19] concluded that use of these CVCs was costeffective [8] . Several points must be considered in the evaluation of this cost analysis. First, as described above, the studies evaluated in the cost analysis suffered significant methodological flaws and only one reported a significant reduction in the rate of CRBSI [10] . Second, chlorhexidine-and silver sulfadiazine-impregnated CVCs did not reduce the key end points associated with cost (i.e., duration of hospital or ICU stay, therapeutic antibiotic use, and duration of catheter retention). Lastly, in the determination of costeffectiveness, this analysis included CVC replacement as a cost variable. CVC replacement is recommended for BSIs due to pathogens such as S. aureus and Candida species, but it is not advocated for CRBSIs caused by CONS. Yet, in the studies included in the cost analysis, the majority of CRBSIs were attributed to CONS [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] 19] . Therefore, the inclusion of CVC replacement as a cost variable in the analysis was not valid. Given these considerations, we believe the cost-effectiveness of antimicrobial-impregnated CVCs remains unclear.
It is also important to note that there are also some concerns about the toxicity associated with use of antimicrobialimpregnated CVCs. Serious acute anaphylactoid toxicity associated with the use of chlorhexidine-and sulfadiazine-impregnated CVCs has been reported several years after the introduction of these CVCs [61, 62] . Similar toxicity issues may emerge with the use of minocycline-and rifampin-impregnated CVCs, given the potential of these 2 agents to cause serious drug-related adverse events, such as a lupus-like syndrome associated with minocycline [63, 64] .
Finally, concerns about the emergence of antimicrobial resistance associated with use of these antibiotic-impregnated CVCs need to be kept in mind, given the potential of these agents to leach out of CVCs [65] . Significant increases in the MICs of both minocycline and rifampin with respect to Staphylococcus epidermidis and Escherichia coli were reported in an in vitro study [66] . It has been argued that the use of 2 very active agents (minocycline and rifampin) is likely to prevent the emergence of resistance [18] . However, when rifampin and nafcillin were administered together, a 75% rate of resistance to rifampin was detected within 1 week after administration [67] . Emergence of resistance to the rifamycins and the cyclines would deprive us of 2 important classes of antimicrobial agents.
CONCLUSION
Our findings indicate that the reported success of antimicrobial-impregnated CVCs in preventing CRBSI is questionable. Furthermore, all the studies reviewed suffer from serious methodological flaws. In light of the lack of supporting evidence for their efficacy and the high cost, risk of resistance, and potential toxicities associated with their use, we submit that the routine use of antimicrobial-impregnated CVCs should be reevaluated.
Future studies evaluating the use of antimicrobial-impregnated CVCs for preventing CRBSI should be conducted in a rigorous fashion. The investigators should (1) follow appropriate methods, including performance of blinding and intentto-treat analysis; calculation of confidence intervals, sample size, and statistical power; and use of multivariate analysis to eliminate the impact of confounding variables; (2) include measurements of patients' severity of illness, degree of immunosuppression, and days at risk; (3) use clinically relevant end points, including duration of catheter retention, duration of hospital or ICU stay, and therapeutic antibiotic use; (4) provide a breakdown of infections based on the offending pathogen and the number of positive culture results; (5) perform molecular-relatedness tests to include skin and mucosal sites; (6) include appropriate evaluation of the risk of emergence of antimicrobial resistance; and (7) provide adequate follow-up and evaluation of adverse events.
